stoxline Quote Chart Rank Option Currency Glossary
  
Apogee Therapeutics, Inc. (APGE)
46.91  -1.44 (-2.98%)    04-19 16:00
Open: 48.01
High: 49.66
Volume: 473,722
  
Pre. Close: 48.35
Low: 45.74
Market Cap: 2,694(M)
Technical analysis
2024-04-19 5:07:45 PM
Short term     
Mid term     
Targets 6-month :  72.19 1-year :  83.8
Resists First :  61.81 Second :  71.75
Pivot price 55.2
Supports First :  45.74 Second :  38.05
MAs MA(5) :  50.09 MA(20) :  58.09
MA(100) :  40.42 MA(250) :  0
MACD MACD :  -2 Signal :  -0.1
%K %D K(14,3) :  4.6 D(3) :  4.3
RSI RSI(14): 35.7
52-week High :  72.29 Low :  14.18
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ APGE ] has closed above bottom band by 5.7%. Bollinger Bands are 33.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 49.76 - 50.04 50.04 - 50.35
Low: 44.99 - 45.29 45.29 - 45.61
Close: 46.34 - 46.87 46.87 - 47.43
Company Description

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Headline News

Thu, 18 Apr 2024
Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 6.1% - MarketBeat

Wed, 17 Apr 2024
Apogee Therapeutics (NASDAQ:APGE) Trading Up 3.3% - MarketBeat

Thu, 28 Mar 2024
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why - Yahoo Finance

Tue, 12 Mar 2024
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option ... - GlobeNewswire

Thu, 07 Mar 2024
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering - GlobeNewswire

Wed, 06 Mar 2024
Insiders Of Apogee Therapeutics Reap Rewards After Their Investment Jumps Another US$74m - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 45 (M)
Shares Float 31 (M)
Held by Insiders 11.3 (%)
Held by Institutions 95 (%)
Shares Short 4,600 (K)
Shares Short P.Month 3,130 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.5
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -21 %
Return on Equity (ttm) -32.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -75 (M)
Levered Free Cash Flow -46 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 6.25
Price to Sales 0
Price to Cash Flow -28.22
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android